Search Results for "pramipexole"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for pramipexole. Results 11 to 14 of 14 total matches.
See also: Mirapex
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
inhalation10 84 mg inhaled 1-5x/day prn 997.50
Dopamine Agonists
Oral
Pramipexole – generic 0.125, 0.25, 0.5 ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
Pramipexole – generic
Mirapex (Boehringer
Ingelheim)
0.125, 0.25, 0.5, 0.75, 1,
1.5 mg tabs
0.5-1.5 mg PO ...
View the Comparison Table: Drugs for Parkinson's Disease
Vorinostat (Zolinza) for Cutaneous T-cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007 (Issue 1256)
Letter:
Pramipexole (Mirapex) for RLS
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
Dermal ...
Vorinostat (Zolinza - Merck), an oral histone deacetylase (HDAC) inhibitor, has received accelerated approval from the FDA for treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) that is persistent, progressive or recurrent after two systemic therapies. The most common types of CTCL are mycosis fungoides and SΘzary syndrome, the leukemic form of mycosis fungoides.
Paliperidone (Invega) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007 (Issue 1256)
and Therapeutics
Coming Soon in The Medical Letter:
Pramipexole (Mirapex) for RLS
Once-Daily Mesalamine (Lialda ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.